{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:30:42Z","timestamp":1773235842281,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T00:00:00Z","timestamp":1345680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in high risk type 2 diabetes patients, the effect of dual RAAS inhibition in patients with non-DM CKD is unclear. The aim of this study was to evaluate the potential renoprotective effect of add-on direct renin inhibitor in non-DM CKD patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively enrolled 189 non-DM CKD patients who had been taking angiotensin II receptor blockers (ARBs) for more than six months. Patients were divided into an add-on aliskiren group and an ARB monotherapy group. The primary outcomes were a decline in glomerular filtration rate (GFR) and a reduction in urinary protein-to-creatinine ratio at six months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The baseline characteristics of the two groups were similar. Aliskiren 150 mg daily reduced the urinary protein-to-creatinine ratio by 26% (95% confidence interval, 15 to 37%; p\u2009&lt;\u20090.001). The decline in GFR was smaller in the add-on aliskiren group (\u22122.1 vs. -4.0 ml\/min, p\u2009=\u20090.038). Add-on aliskiren had a neutral effect on serum potassium in the non-DM CKD patients. In subgroup analysis, the proteinuria-reducing effect of aliskiren was more prominent in patients with a GFR less than 60 ml\/min, and in patients with a urinary protein-to-creatinine ratio greater than 1.8. The effect of aliskiren in retarding the decline in GFR was more prominent in patients with hypertensive nephropathy than in those with glomerulonephritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Add-on direct renin inhibitor aliskiren (150 mg daily) safely reduced proteinuria and attenuated the decline in GFR in the non-DM CKD patients who were receiving ARBs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-13-89","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:14:01Z","timestamp":1345767241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Szu-yuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Tai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Chang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ching","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,23]]},"reference":[{"issue":"2","key":"382_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10741-011-9262-2","volume":"17","author":"NF Schroten","year":"2012","unstructured":"Schroten NF, Gaillard CA, van Veldhuisen DJ, Szymanski MK, Hillege HL, de Boer RA: New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev. 2012, 17 (2): 191-201. 10.1007\/s10741-011-9262-2.","journal-title":"Heart Fail Rev"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"99","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005, 99: S57-S65.","journal-title":"Kidney Int Suppl"},{"issue":"20","key":"382_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med. 1998, 339 (20): 1448-1456. 10.1056\/NEJM199811123392007.","journal-title":"N Engl J Med"},{"issue":"8","key":"382_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2337\/diab.43.8.1046","volume":"43","author":"JL Taft","year":"1994","unstructured":"Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes. 1994, 43 (8): 1046-1051. 10.2337\/diabetes.43.8.1046.","journal-title":"Diabetes"},{"issue":"3","key":"382_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ki.1991.57","volume":"39","author":"FN Ziyadeh","year":"1991","unstructured":"Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991, 39 (3): 464-475. 10.1038\/ki.1991.57.","journal-title":"Kidney Int"},{"issue":"9069","key":"382_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997, 349 (9069): 1857-1863.","journal-title":"Lancet"},{"issue":"4","key":"382_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5414\/CN107013","volume":"76","author":"SM Titan","year":"2011","unstructured":"Titan SM, M. Vieira J J, Dominguez WV, Barros RT, Zatz R: ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. Clinical nephrology. 2011, 76 (4): 273-83.","journal-title":"Clinical nephrology"},{"key":"382_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2369-12-41","volume":"12","author":"S Hull","year":"2011","unstructured":"Hull S, Dreyer G, Badrick E, Chesser A, Yaqoob MM: The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrology. 2011, 12: 41-10.1186\/1471-2369-12-41.","journal-title":"BMC Nephrology"},{"issue":"15","key":"382_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996, 334 (15): 939-945. 10.1056\/NEJM199604113341502.","journal-title":"N Engl J Med"},{"issue":"2","key":"382_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, et al: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006, 354 (2): 131-140. 10.1056\/NEJMoa053107.","journal-title":"N Engl J Med"},{"issue":"40","key":"382_CR11","first-page":"5519","volume":"163","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Ugeskr Laeger. 2001, 163 (40): 5519-5524.","journal-title":"Ugeskr Laeger"},{"issue":"15","key":"382_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358 (15): 1547-1559.","journal-title":"N Engl J Med"},{"issue":"5","key":"382_CR13","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","volume":"24","author":"HH Parving","year":"2009","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, et al: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2009, 24 (5): 1663-1671. 10.1093\/ndt\/gfn721.","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"3","key":"382_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/ajh.2010.231","volume":"24","author":"O Gross","year":"2011","unstructured":"Gross O, Girgert R, Rubel D, Temme J, Theissen S, Muller GA: Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens. 2011, 24 (3): 355-361. 10.1038\/ajh.2010.231.","journal-title":"Am J Hypertens"},{"issue":"5","key":"382_CR15","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","volume":"58","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000, 58 (5): 2084-2092. 10.1111\/j.1523-1755.2000.00381.x.","journal-title":"Kidney Int"},{"issue":"5","key":"382_CR16","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1046\/j.1523-1755.2000.00058.x","volume":"57","author":"SG Adler","year":"2000","unstructured":"Adler SG, Feld S, Striker L, Striker G, LaPage J, Esposito C, Aboulhosn J, Barba L, Cha DR, Nast CC: Glomerular type IV collagen in patients with diabetic nephropathy with and without additional glomerular disease. Kidney Int. 2000, 57 (5): 2084-2092. 10.1046\/j.1523-1755.2000.00058.x.","journal-title":"Kidney Int"},{"key":"382_CR17","volume-title":"Hsu HJ","author":"CY Sun","year":"2011","unstructured":"Sun CY, Cherng WJ, Jian HZ, Hsu HH, Wu IW: Hsu HJ. 2011, Wu MS: Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury-beyond the direct renin inhibition. Hypertens Res"},{"issue":"Suppl 2","key":"382_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1440-1797.2010.01309.x","volume":"15","author":"N Chen","year":"2010","unstructured":"Chen N, Hsu CC, Yamagata K, Langham R: Challenging chronic kidney disease: experience from chronic kidney disease prevention programs in Shanghai, Japan, Taiwan and Australia. Nephrology (Carlton). 2010, 15 (Suppl 2): 31-36.","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"382_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1440-1797.2009.01154.x","volume":"15","author":"SY Wei","year":"2010","unstructured":"Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC, Huang CJ, Chen HC, Hwang SJ: Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology (Carlton). 2010, 15 (1): 108-115. 10.1111\/j.1440-1797.2009.01154.x.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"382_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470.","journal-title":"Ann Intern Med"},{"issue":"9176","key":"382_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999, 354 (9176): 359-364. 10.1016\/S0140-6736(98)10363-X.","journal-title":"Lancet"},{"issue":"12","key":"382_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345 (12): 851-860. 10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"issue":"9079","key":"382_CR23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(05)63539-8","volume":"350","author":"AM Porter","year":"1997","unstructured":"Porter AM: Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study. Lancet. 1997, 350 (9079): 736-author reply 736\u2013737","journal-title":"Lancet"},{"issue":"23","key":"382_CR24","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008, 358 (23): 2433-2446. 10.1056\/NEJMoa0708379.","journal-title":"N Engl J Med"},{"issue":"11","key":"382_CR25","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.2337\/dc10-0833","volume":"33","author":"F Persson","year":"2010","unstructured":"Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH: Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010, 33 (11): 2304-2309. 10.2337\/dc10-0833.","journal-title":"Diabetes Care"},{"key":"382_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000325650","volume":"170","author":"SC Tang","year":"2011","unstructured":"Tang SC, Leung JC, Lai KN: The kallikrein-kinin system. Contrib Nephrol. 2011, 170: 145-155.","journal-title":"Contrib Nephrol"},{"issue":"5","key":"382_CR27","doi-asserted-by":"publisher","first-page":"F929","DOI":"10.1152\/ajprenal.00192.2010","volume":"299","author":"WP Wu","year":"2010","unstructured":"Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ: A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol. 2010, 299 (5): F929-F941. 10.1152\/ajprenal.00192.2010.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"382_CR28","first-page":"694","volume":"186","author":"DE Choi","year":"2011","unstructured":"Choi DE, Jeong JY, Lim BJ, Chang YK, Na KR, Shin YT, Lee KW: Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. JUrol. 2011, 186 (2): 694-701.","journal-title":"JUrol"},{"issue":"4","key":"382_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","volume":"1","author":"MR Weir","year":"2007","unstructured":"Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am SocHypertens. 2007, 1 (4): 264-277.","journal-title":"J Am SocHypertens"},{"issue":"8","key":"382_CR30","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1016\/j.transproceed.2010.07.053","volume":"42","author":"V L\u00f3pez","year":"2010","unstructured":"L\u00f3pez V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Mart\u00ednez D, Hernandez D: Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc. 2010, 42 (8): 2883-2885. 10.1016\/j.transproceed.2010.07.053.","journal-title":"Transplant Proc"},{"issue":"2","key":"382_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ndt\/gfr349","volume":"27","author":"SC Tang","year":"2012","unstructured":"Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW, Lai KN: Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant. 2012, 27 (2): 613-618. 10.1093\/ndt\/gfr349.","journal-title":"Nephrol Dial Transplant"},{"key":"382_CR32","volume-title":"J Renin Angiotensin Aldosterone Syst","author":"T Nakamura","year":"2011","unstructured":"Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi SI: Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst. 2011"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-89.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-13-89\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-13-89.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:25:34Z","timestamp":1630527934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-13-89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-13-89","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,23]]},"assertion":[{"value":"2 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"89"}}